Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels

Inclusion Criteria: * Male or non-nursing female patients 18-75 years of age, inclusive, at the time of Screening * Previous diagnosis of PiZZ genotype Alpha-1 Antitrypsin Deficiency (AATD) * Non-smoker (not a daily cigarette smoker) for at least three years with current non-smoking status confirmed by urine cotinine at screening. * Highly effective, double barrier contraception (both male and female partners) during the study and for 3 months following the last dose of ARC-AAT Injection * Suitable venous access for blood sampling Exclusion Criteria: * Known diagnosis of hepatic fibrosis from a cause other than AATD * History of poorly controlled autoimmune disease, or any history of autoimmune hepatitis * Human immunodeficiency virus (HIV) infection * Seropositive for Hepatitis B virus (HBV) or Hepatitis C virus (HCV) * Uncontrolled hypertension * History of cardiac rhythm disturbances * Symptomatic heart failure, unstable angina, myocardial infarction, severe cardiovascular disease, transient ischemic attack (TIA) or cerebrovascular accident (CVA) within 6 months prior to study entry * History of malignancy within the last 2 years except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer * History of major surgery within 1 month of Screening * Regular use of alcohol within one month prior to the Screening visit * Use of illicit drugs (such as cocaine, phencyclidine \[PCP\] and crack) within 1 year prior to Screening or positive urine drug screen at Screening * Use of an investigational agent or device within 30 days prior to dosing or current participation in an investigational study involving a therapeutic intervention * Any clinically significant history/presence of an uncontrolled systemic disease * Blood donation (≥500 mL) within 7 days prior to study treatment administration